查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1820223

2025 年至 2033 年抗生素市场规模、份额、趋势及预测（依作用机转、药物类别、活性范围、给药途径、最终用户及地区划分）

Antibiotics Market Size, Share, Trends and Forecast by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球抗生素市场规模达533亿美元。预计到2033年，该市场规模将达到738亿美元，2025-2033年期间的复合年增长率为3.3%。亚太地区目前占据市场主导地位，2024年将占据约44%的市场。肺炎、结核病和其他传染病病例的增加推动了市场的发展。人们对抗生素抗药性的日益担忧正推动着新型、更有效的抗生素疗法的发展。此外，发展中地区医疗保健服务的不断扩大也支持了抗生素消费量的增加。此外，生物技术和药物研发技术的持续进步也是扩大抗生素市场份额的主要因素之一。

目前，全球人口中慢性病的盛行率不断上升，推动了市场的成长。此外，抗生素透过线上线下商店的广泛供应以及对外用抗生素需求的增加，也推动了产品需求的成长。抗生素有助于降低患者手术伤口感染的风险，这增强了全球对抗生素的需求。为了牲畜的健康和福祉，抗生素的使用量不断增加，也推动了市场的成长。此外，消费者对预防性医疗保健措施的意识不断增强，以及老龄化人口需求的成长，也支持了抗生素市场的成长。

美国抗生素市场正经历利润丰厚的成长，这得益于持续的细菌感染治疗需求以及日益严重的抗生素抗药性问题。科学研究投入和政府支持的措施正在推动更有效治疗方法的发展。一个显着的例子是美国食品药物管理局 (FDA) 于 2023 年 4 月批准的 Zevtera（注射头孢比普利美多卡利钠），该药物旨在治疗金黄色葡萄球菌血流感染（菌血症），包括右侧感染性心内膜炎和急性细菌性皮肤感染。

抗生素市场趋势：

传染病发生率上升

在全球范围内，肺炎、肺结核、泌尿道感染 (UTI)、胃肠道感染和血液败血症等传染病的发生率正在上升，而由于卫生条件差，人们患这些疾病的几率也随之上升。这加剧了细菌感染的传播。每 25 名女性中就有 10 名，每 25 名男性中就有 3 名在一生中的某个阶段患有泌尿道感染。我们需要更强效的抗生素来帮助治疗这些感染。抗生素专门用于靶向和消除细菌感染。它们能有效杀死体内细菌并促进癒合。此外，抗生素也需要在医疗专业人员的指导下使用，以优化患者的预后。

抗菌素抗药性（AMR）的发生率不断上升

在全球范围内，抗菌素抗药性 (AMR) 的发生率呈上升趋势，这推动了抗生素市场的发展。当细菌、病毒、寄生虫或真菌进化并对用于治疗它们的药物产生抗药性时，就会发生 AMR。它会降低抗生素的有效性，导致感染持续时间更长、病情更严重，增加医疗成本，并导致个人死亡率高。 2019 年，细菌抗菌素抗药性 (AMR) 与全球 127 万人死亡直接相关。抗生素的过度使用和滥用导致抗药性细菌的产生，从而降低传统抗生素的疗效。此外，抗甲氧西林金黄色葡萄球菌 (MRSA) 和耐碳青霉烯肠桿菌科细菌 (CRE) 等多重抗药性菌株更为常见。这需要销售和开发先进的抗生素，从而促进市场成长。

抗生素技术进步

生物技术、分子生物学和药物发现技术的创新正在帮助提高抗生素开发的效率和有效性。这反过来又增强了抗生素市场的前景。基因组学和高通量筛选使得识别潜在的药物标靶和筛选大型化合物库成为可能。许多公司正在投资这项技术。例如，2021 年 1 月，辉瑞宣布根据辉瑞突破性成长计画 (PBGI) 向四家临床阶段生技公司投资 1.2 亿美元。该合作旨在根据辉瑞未来的战略利益推进有前景的临床开发项目。电脑辅助药物设计还可以预测药物疗效和优化抗生素候选物。这些技术进步简化了抗生素发现过程，与传统方法相比，减少了时间和成本。此外，快速病原体鑑定和敏感性测试等诊断技术的进步有助于选择合适的抗生素以改善患者预后。

疾病负担、抗药性和地区差异导致需求上升

由于全球健康压力日益增加，市场正在稳步增长。传染病的发生率不断上升，尤其是在中低收入国家，这推动了对广谱抗生素的需求增加。产业报告显示，2023年记录了约820万例新发结核病病例，较2022年的750万例增加。呼吸道感染、泌尿道感染和胃肠道疾病仍然特别常见，促使全球医疗保健系统依赖抗生素作为第一线治疗。同时，全球范围内的抗生素抗药性正在加剧，降低了旧疗法的有效性，并迫使人们开发新的药物类别。第一线抗生素的抗药性增加，导致治疗失败和住院时间延长。这促使公共和私营部门对新型化合物和改进诊断方法进行投资。此外，抗生素使用和取得的地理分布差异很大。高收入国家强调监测和管理，而许多中低收入地区则面临获取受限、品质不稳定和滥用的问题。这种不平衡增加了全球市场政策和供应链策略的复杂性。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球抗生素市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场分化：按作用机制

  • 细胞壁合成抑制剂
  • 蛋白质合成抑制剂
  • DNA合成抑制剂
  • RNA合成抑制剂
  • 霉菌酸抑制剂
  • 其他的

第七章：市场区隔：依药品类别

  • 头孢菌素
  • 青霉素
  • 氟喹诺酮类药物
  • 大环内酯类
  • 卡巴培南
  • 氨基糖苷类
  • 其他的

第八章：市场区隔：依活动范围

  • 广效抗生素
  • 窄谱抗生素

第九章：市场细分：依行政途径

  • 口服
  • 肠外
  • 外用
  • 其他的

第 10 章：市场区隔：依最终用户

  • 医院
  • 专科诊所
  • 其他的

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 12 章：SWOT 分析

第 13 章：价值链分析

第 14 章：波特五力分析

第 15 章：价格分析

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Allergan Plc (AbbVie Inc.)
    • Basilea Pharmaceutica AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Melinta Therapeutics
    • Merck & Co. Inc.
    • Nabriva Therapeutics Plc
    • Paratek Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Spero Therapeutics
    • Tetraphase Pharmaceuticals
Product Code: SR112025A3569

The global antibiotics market size was valued at USD 53.3 Billion in 2024. The market is projected to reach USD 73.8 Billion by 2033, exhibiting a CAGR of 3.3% during 2025-2033. Asia Pacific currently dominates the market, holding a significant market share of around 44% in 2024. The market is fueled by the increasing cases of pneumonia, tuberculosis, and other infectious diseases among individuals. The increasing concerns over antimicrobial resistance are driving the development of new and more effective antibiotic therapies. Also, expanding healthcare access in developing regions is supporting greater antibiotic consumption. In addition to this, continual technological advancements in biotechnology and drug discovery techniques are some of the major factors augmenting the antibiotics market share.

Currently, the increasing prevalence of chronic diseases in the global population is contributing to the market growth. Moreover, the widespread availability of antibiotics through online and offline stores and increased demand for topical antibiotics are boosting the product demand. Antibiotics help reduce the risk of infection in the surgical wound area for individuals. This has strengthened the global demand for antibiotics. Rising employment of antibiotics for the health and welfare of livestock animals is also fueling the market growth. In addition, the increased consumer awareness of preventative health care measures and growing demand in aging population are supporting the antibiotics market growth.

The antibiotics market in the United States is witnessing lucrative growth, fueled by the ongoing need to treat bacterial infections and the growing issue of antibiotic resistance. Investments in research and government-backed initiatives are encouraging the development of more effective treatments. A notable example is the FDA's approval in April 2023 of Zevtera (ceftobiprole medocaril sodium for injection), which is designed to treat Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis and acute bacterial skin infections.

Antibiotics Market Trends:

Rising Incidence of Infectious Diseases

Worldwide, the incidence of infectious diseases such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections and sepsis in the bloodstream is increasing among the population and people suffer more from these diseases because of inadequate sanitation. This contributes to the spread of bacterial infections. 10 out of 25 women and 3 out of 25 men have a urinary tract infection at some point in their lives. More powerful antibiotics are needed to help treat these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing. Antibiotics are also used under the guidance of a health professional to optimize patient outcomes.

Increasing Occurrence of Antimicrobial Resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. In 2019, bacterial antimicrobial resistance (AMR) was directly linked to 1.27 million deaths worldwide. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the sales and development of advanced antibiotics, thereby contributing to the market growth.

Technological Advancements in Antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques are helping to improve the efficiency and effectiveness of antibiotic development. This, in turn, is enhancing the antibiotics market outlook. Genomics and high-throughput screening enable the identification of potential drug targets and the screening of large compound libraries. Many companies are investing in the technology. For example, in January 2021, Pfizer Inc. announced a $120 million investment in four clinical-stage biotechnology companies under the Pfizer Breakthrough Growth Initiative (PBGI). The partnership aims to advance promising clinical development programs in line with Pfizer's future strategic interests. Computer-aided drug design also allows for predicting drug efficacy and optimizing antibiotic candidates. These technological advances have streamlined the antibiotic discovery process and reduce the time and costs compared to traditional methods. In addition, advances in diagnostic techniques, such as rapid pathogen identification and sensitivity testing, help in choosing the right antibiotic to improve patient outcomes.

Rising Demand due to Disease Burden, Resistance, and Regional Disparities

The market is experiencing steady growth due to increasing global health pressures. The rising prevalence of infectious diseases, particularly in low- and middle-income countries, is driving higher demand for broad-spectrum antibiotics. Industry reports indicate that approximately 8.2 million new tuberculosis cases were recorded in 2023, reflecting an increase from 7.5 million cases in 2022. Respiratory infections, urinary tract infections, and gastrointestinal disorders remain especially common, prompting healthcare systems worldwide to rely on antibiotics as frontline therapy. Concurrently, antimicrobial resistance is intensifying worldwide, reducing the effectiveness of older treatments and forcing the development of new drug classes. Resistance to first-line antibiotics has increased, leading to treatment failures and longer hospital stays. This has spurred public and private sector investments in novel compounds and improved diagnostics. Moreover, the geographic distribution of antibiotic usage and access varies significantly. High-income countries emphasize surveillance and stewardship, while many low- and middle-income regions face limited access, inconsistent quality, and misuse. This imbalance adds complexity to policy and supply chain strategies across the global market.

Antibiotics Industry Segmentation:

Analysis by Action Mechanism:

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others

Cell wall synthesis inhibitors action mechanism is the largest action mechanism in 2024, holding around 52% market share. Cell wall synthesis inhibitors is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Analysis by Drug Class:

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolide
  • Carbapenem
  • Aminoglycoside
  • Others

Penicillin leads the market with around 26% market share in 2024. As per antibiotics market report segmentation, Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is increasingly used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Analysis by Activity:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics segment leads the market with around 70% market share in 2024. Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Analysis by Route of Administration:

  • Oral
  • Parenteral
  • Topical
  • Others

Parenteral leads the market with over 68% market share in 2024. Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Analysis by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Hospitals leads the market with around 60% market share in 2024. Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, Asia-Pacific accounted for the largest market share of around 44%. The growing incidence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

Key Regional Takeaways:

North America Antibiotics Market Analysis:

The North America antibiotics market is driven by the increasing incidence of infectious diseases, particularly respiratory infections, and urinary tract infections, as these conditions necessitate effective antibiotic treatments to combat rising bacterial resistance. Additionally, the aging population in the region contributes to heightened demand for antibiotics, as older adults are more susceptible to infections. Advances in antibiotic development, including novel formulations and combination therapies, are also critical in addressing antibiotic resistance challenges. Furthermore, strategic collaborations among pharmaceutical companies and increased investment in research and development are enhancing the pipeline of new antibiotics, ensuring the market remains responsive to evolving health needs.

United States Antibiotics Market Analysis:

United States accrued a market share of around 86% in the North America market in 2024. The increased incidence of bacterial illnesses, improvements in healthcare facilities, and significant R&D expenditures are the main factors propelling the U.S. antibiotics industry. Urinary tract infections and respiratory tract infections continued to be among the most frequently treated illnesses in 2023, which increased the need for a wide range of antibiotics. The market is greatly influenced by the aging population, which is expected to reach more than 78 million by 2040 and more than 88 million by 2060. This is because older people are more prone to illnesses. Also, one of the significant antibiotics market trends is the rise of strains of bacteria that are resistant to antibiotics, like MRSA, which is increasing the demand for next-generation antibiotics and sparked innovation in the pharmaceutical industry.

Research on new antibiotic classes and quick diagnostics are supported by government programs to address antimicrobial resistance (AMR), such as the National Action Plan for Combating Antibiotic-Resistant Bacteria. Additionally, market expansion is driven by the FDA's accelerated approval processes for important medicines and the robust presence of major pharmaceutical companies in the United States. Demand is being further fueled by healthcare facilities implementing stricter antibiotic regimens in response to an increase in hospital-acquired infections (HAIs). The U.S. market for antibiotics is expanding despite issues with overuse and resistance, owing to strong healthcare spending and innovation.

Europe Antibiotics Market Analysis:

The growing cases of infectious diseases and the numerous government programs designed to fight antibiotic resistance are the main factors affecting the antibiotics market in Europe. According to the World Health Organization (WHO), Europe uses a diverse range of antibiotics and has a high rate of resistant bacterial strains, including Klebsiella pneumonia and E. coli. As a result, the players are investing in the creation of novel antibiotics and stewardship initiatives to maximize their use.

Leading countries in this sector include Germany, France, and the United Kingdom, bolstered by their sophisticated healthcare systems and proactive AMR regulations. Additionally, the EMA has expedited the approval procedures for antibiotics that fulfill unmet medical requirements. The increase of outpatient care services and the increasing use of quick diagnostic techniques for bacterial infections are driving the market demand further.

Asia Pacific Antibiotics Market Analysis:

The high incidence of infectious diseases, rising healthcare costs, and growing awareness of contemporary treatments are all contributing to the Asia-Pacific antibiotics market's rapid expansion. Antibiotic demand is fueled by the high incidence of bacterial illnesses, such as pneumonia and tuberculosis, in nations like China, Indonesia, and India. According to time-series research, a total of 16,290 million doses of antibiotics were sold in India in 2020, which is slightly less than the amount in 2018 and 2019. Apart from this, the antibiotics market worth is further increased by the expanding middle class and better access to healthcare services in emerging markets.

The region's governments are tackling issues such as antibiotic resistance by supporting antibiotic stewardship initiatives and providing funds for research into novel medication classes. As significant producers of antibiotics, China and India also gain from export prospects. Additionally, the use of telemedicine platforms is expanding the availability of antibiotic treatments in remote locations.

Latin America Antibiotics Market Analysis:

The incidence of infectious disorders, such as gastrointestinal and respiratory infections, is propelling the Latin American market growth. Advanced antibiotics are being adopted by nations like Brazil and Mexico to fight infections that are worsened by inadequate access to healthcare and poor sanitation. The industry is expanding owing to government programs like vaccination campaigns that use preventative antibiotics and investments in healthcare infrastructure. Furthermore, the region's expanding pharmaceutical sector and collaborations with international pharmaceutical companies are opportunistic for the market growth.

Middle East and Africa Antibiotics Market Analysis:

The high incidence of infectious diseases, including respiratory infections, malaria, and tuberculosis, has an impact on the demand for antibiotics. Antibiotics are becoming more widely available in the Middle East due to the investments made in healthcare modernization by nations like Saudi Arabia and the United Arab Emirates. International agencies like UNICEF and WHO are assisting antibiotic supply chains in Africa to address healthcare issues. While government programs are encouraging local production to lessen reliance on imports, awareness campaigns and measures to combat antibiotic resistance are gradually improving usage patterns.

Competitive Landscape:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focus on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misuse. According to antibiotics market research report, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report provides a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allergan Plc (AbbVie Inc.)
  • Basilea Pharmaceutica AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck & Co. Inc.
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals

Key Questions Answered in This Report

  • 1.How big is the antibiotics market?
  • 2.What is the future outlook of the antibiotics market?
  • 3.What are the key factors driving the antibiotics market?
  • 4.Which region accounts for the largest antibiotics market share?
  • 5.Which are the leading companies in the global antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Action Mechanism

  • 6.1 Cell Wall Synthesis Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Protein Synthesis Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Synthesis Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 RNA Synthesis Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Mycolic Acid Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cephalosporin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Penicillin
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Fluoroquinolone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Macrolide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Carbapenem
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Aminoglycoside
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Spectrum of Activity

  • 8.1 Broad-Spectrum Antibiotics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Narrow-Spectrum Antibiotics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Topical
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Specialty Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Allergan Plc (AbbVie Inc.)
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica AG
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 GlaxoSmithKline Plc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Johnson & Johnson
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Melinta Therapeutics
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Merck & Co. Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Nabriva Therapeutics Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Paratek Pharmaceuticals Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Pfizer Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sanofi SA
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Spero Therapeutics
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
    • 16.3.12 Tetraphase Pharmaceuticals
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Antibiotics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antibiotics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antibiotics Market: Breakup by Action Mechanism (in %), 2024
  • Figure 5: Global: Antibiotics Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Antibiotics Market: Breakup by Spectrum of Activity (in %), 2024
  • Figure 7: Global: Antibiotics Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Antibiotics Market: Breakup by End User (in %), 2024
  • Figure 9: Global: Antibiotics Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antibiotics (Protein Synthesis Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antibiotics (Protein Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antibiotics (DNA Synthesis Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antibiotics (DNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antibiotics (RNA Synthesis Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antibiotics (RNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antibiotics (Mycolic Acid Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antibiotics (Mycolic Acid Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antibiotics (Other Action Mechanisms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antibiotics (Other Action Mechanisms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antibiotics (Cephalosporin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antibiotics (Cephalosporin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antibiotics (Penicillin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antibiotics (Penicillin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antibiotics (Fluoroquinolone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antibiotics (Fluoroquinolone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antibiotics (Macrolide) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antibiotics (Macrolide) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antibiotics (Carbapenem) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antibiotics (Carbapenem) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Antibiotics (Aminoglycoside) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Antibiotics (Aminoglycoside) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Antibiotics (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Antibiotics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Antibiotics (Broad-Spectrum Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Antibiotics (Broad-Spectrum Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Antibiotics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Antibiotics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Antibiotics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Antibiotics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Antibiotics (Topical) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Antibiotics (Topical) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Antibiotics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Antibiotics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Antibiotics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Antibiotics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Antibiotics (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Antibiotics (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Global: Antibiotics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Global: Antibiotics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: North America: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: North America: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United States: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United States: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Canada: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Canada: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Asia-Pacific: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Asia-Pacific: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: China: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: China: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Japan: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Japan: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: India: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: India: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: South Korea: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: South Korea: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Australia: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Australia: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Indonesia: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Indonesia: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Europe: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Europe: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Germany: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Germany: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: France: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: France: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: United Kingdom: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: United Kingdom: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Italy: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Italy: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Spain: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Spain: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Russia: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Russia: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Others: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Latin America: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Latin America: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Brazil: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Brazil: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Mexico: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Mexico: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Others: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 100: Middle East and Africa: Antibiotics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 101: Middle East and Africa: Antibiotics Market: Breakup by Country (in %), 2024
  • Figure 102: Middle East and Africa: Antibiotics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 103: Global: Antibiotics Industry: SWOT Analysis
  • Figure 104: Global: Antibiotics Industry: Value Chain Analysis
  • Figure 105: Global: Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibiotics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antibiotics Market Forecast: Breakup by Action Mechanism (in Million USD), 2025-2033
  • Table 3: Global: Antibiotics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million USD), 2025-2033
  • Table 5: Global: Antibiotics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Antibiotics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 7: Global: Antibiotics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Antibiotics Market: Competitive Structure
  • Table 9: Global: Antibiotics Market: Key Players